Enovis (NYSE:ENOV) EVP Sells $27,172.80 in Stock

Enovis Corporation (NYSE:ENOV) EVP Daniel Pryor sold 999 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Enovis Stock Performance

NYSE ENOV traded up $0.16 on Thursday, hitting $27.83. 921,341 shares of the company’s stock were exchanged, compared to its average volume of 759,457. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -1.18 and a beta of 1.52. The firm’s 50-day moving average price is $30.22 and its two-hundred day moving average price is $30.57. Enovis Corporation has a fifty-two week low of $25.47 and a fifty-two week high of $49.38. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.22 and a quick ratio of 1.16.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. The business had revenue of $383.81 million during the quarter. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%. On average, research analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

Analysts Set New Price Targets

ENOV has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a report on Wednesday, October 8th. Wells Fargo & Company lifted their price target on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and an average target price of $51.17.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Rubric Capital Management LP purchased a new stake in Enovis in the 3rd quarter valued at approximately $83,435,000. Vanguard Group Inc. lifted its position in shares of Enovis by 11.3% in the first quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company’s stock valued at $233,356,000 after acquiring an additional 621,069 shares in the last quarter. Tributary Capital Management LLC boosted its stake in shares of Enovis by 91.5% during the third quarter. Tributary Capital Management LLC now owns 1,154,482 shares of the company’s stock valued at $35,027,000 after acquiring an additional 551,613 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in Enovis by 191.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 810,771 shares of the company’s stock worth $26,772,000 after purchasing an additional 532,648 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after purchasing an additional 434,646 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.